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Protontherapy is hadrontherapy’s fastest-growing modality and a pillar in the battle against cancer. 
Hadrontherapy’s superiority lies in its inverted depth-dose profile, hence tumour-confined irradiation. 
Protons, however, lack distinct radiobiological advantages over photons or electrons. Higher LET 
(Linear Energy Transfer) 12C-ions can overcome cancer radioresistance: DNA lesion complexity increases 
with LET, resulting in efficient cell killing, i.e. higher Relative Biological Effectiveness (RBE). However, 
economic and radiobiological issues hamper 12C-ion clinical amenability. Thus, enhancing proton RBE is 
desirable. To this end, we exploited the p + 11B → 3α reaction to generate high-LET alpha particles with 
a clinical proton beam. To maximize the reaction rate, we used sodium borocaptate (BSH) with natural 
boron content. Boron-Neutron Capture Therapy (BNCT) uses 10B-enriched BSH for neutron irradiation-
triggered alpha particles. We recorded significantly increased cellular lethality and chromosome 
aberration complexity. A strategy combining protontherapy’s ballistic precision with the higher RBE 
promised by BNCT and 12C-ion therapy is thus demonstrated.
The urgent need for radical radiotherapy research to achieve improved tumour control in the context of reducing 
the risk of normal tissue toxicity and late-occurring sequelae, has driven the fast-growing development of can-
cer treatment by accelerated beams of charged particles (hadrontherapy) in recent decades1. This appears to be 
particularly true for protontherapy, which has emerged as the most-rapidly expanding hadrontherapy approach, 
totalling over 100,000 patients treated thus far worldwide2. Wilson first proposed the use of energetic protons for 
cancer radiotherapy in 19463. The primary motivation for investigation into this area was based on the physical 
properties of charged particles, which can deposit energy far more selectively than photons: through the inverted 
depth-dose profile described by the Bragg curve4, healthy tissues within the entry channel of the beam are spared 
of dose, while most of the dose is steeply confined at the end of the particle range (the so-called “Bragg peak”). 
This in principle enables the delivery of very high-dose gradients close to organs at risk, confining the high-dose 
area to the tumour volume. Despite the dearth of randomized trials showing an effective advantage of protons 
over photon-based radiotherapy5,6 and the ongoing debate over its cost-effectiveness7, the current phase I/II clin-
ical results support the rationale of the approach, especially for deep-seated tumours localized in proximity of 
critical organs, and unresectable or recurrent tumours8,9. Cancer treatment by protons also remains the most 
attractive solution in the case of paediatric patients due to the significant reduction in the integral dose delivered 
to the patient8, even compared to newer photon techniques such as intensity modulated radiation therapy10. 
However, protons have been traditionally regarded as only slightly more biologically effective than photons11. 
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In fact, the standard practice in protontherapy is to adopt an RBE (Relative Biological Effectiveness) value of 1.1 
compared to photons in any clinical condition12, although such an assumption overlooks the increased RBE of 
low-energy protons13–15 disregarding recently unveiled peculiarities of proton radiobiology8,16,17.
The combination of ballistic precision with an increased ability to kill cells is the radiobiological rationale 
currently supporting the clinical exploitation of heavier particles such as fully stripped 12C-ions18, which present 
some advantages over protons6,18. Not only do they ensure a better physical dose distribution, due to less lateral 
scattering19, but they also result more biologically effective both in vitro and in vivo as a result of their higher 
Linear Energy Transfer (LET)11,20,21. In fact, densely ionizing radiation tracks cause more spatio-temporally con-
tiguous and complex lesions at the DNA level, comprising DNA double-strand breaks and damaged bases, which 
are highly clustered in nature22–24. This impairs cellular ability for correct repair25 and decreases the depend-
ence of radiosensitization upon the presence of oxygen, desirable features for eradication of resilient, hypoxic 
tumors5,26. Further potential radiobiological advantages include greater RBE for killing putatively radioresistant 
cancer stem cells27 and counteracting cancer invasiveness28,29, albeit the latter remains controversial30. Finally, low 
doses of high-LET radiation appear to elicit stronger immunological responses compared to low-LET radiation16.
On the other hand, complications related to nuclear fragmentation from the primary beam, along with a 
partial understanding of the consequences of the exposure of normal cells to high-LET radiation, and also consid-
ering the complexity and high costs associated with a 12C treatment facility, fueled research into exploring novel 
strategies with the aim to achieve alternative solutions for a localized increase of proton RBE.
One of such recently proposed approaches foresees the use of gold nanoparticles as protontherapy radiosen-
sitizers31. The ability of particle radiation to stimulate favourable immunological responses represents another 
attractive solution as it has become increasingly evident that proton and photon irradiation differentially modu-
late systemic biological responses8,17.
In this work, we experimentally test for the first time the idea theoretically proposed by Do-Kun Y et al. 
in32, based on the use of the p + 11B → 3α nuclear fusion reaction33,34 to enhance proton biological effectiveness 
exclusively in the tumour region through the generation of short-range high-LET alpha particles, thus being of 
potential clinical worth. Cells were irradiated with a clinical proton beam in the presence of sodium borocap-
tate (NA2B12H11SH or “BSH”), which is a common agent clinically used in BNCT in its 10B-enriched form to 
selectively deliver given boron concentrations in cancer cells35. BNCT requires thermal neutrons to trigger the 
reaction where two charged particles (one alpha of 1.77 MeV and one 7Li ion of 1.015 MeV) with a positive Q 
value of 2.792 MeV are produced36. In order to maximize the p + 11B → 3α fusion rate, we used BSH with natu-
ral occurring boron isotopic abundance (i.e. about 80% 11B and 20% 10B). We observed a significant increase in 
proton-induced cytogenetic effects, both in terms of cell death, assessed as loss of proliferative potential by the 
clonogenic assay, and of induction of DNA damage. The latter was studied by chromosome aberrations revealed 
by Fluorescence In Situ Hybridization (FISH) painting techniques. Specifically, the markedly higher frequency of 
complex-type chromosome exchanges (a typical cytogenetic signature of high-LET ionizing radiation, see ref.37, 
which was found among boron-treated cells compared to proton-irradiated cells in the absence of BSH, points 
to alpha particles generated in the nuclear fusion reaction as being responsible for the measured enhancement 
of proton biological effectiveness. These findings, therefore, yield important implications for an enhanced cancer 
protontherapy.
Results
Experimental approach. The proton-boron nuclear reaction considered in this work is usually formalized 
as p + 11B —> 3α. It has a positive Q-value (8.7 MeV) and is often referred to as “proton-boron fusion reaction” 
since the incident proton is completely absorbed by the 11B nucleus. This reaction has garnered interest since the 
1930s33,34 because of the process ability to produce copious numbers of alpha particles in an exothermic reaction.
According to the most recent studies and interpretations, p + 11B —> 3α can be described as a two-step 
reaction (involving 12C and 8Be nuclei excitation) with a main resonance occurring at a 675 keV (center of mass 
energy) and where the maximum cross section of 1.2 barn is measured38,39. A more detailed description of the 
reaction is reported in Methods. The emitted alpha particles exhibit a wide energy spectrum with a predominant 
energy around 4 MeV40. Such a reaction has been considered very attractive for the generation of fusion energy 
without producing neutron-induced radioactivity41,42.
Such a nuclear reaction may be even more useful as it could play a strategic role in medical applications 
improving the effectiveness of protontherapy. The potential clinical use of the p-11B reaction has been thus far 
only investigated and validated by means of Monte Carlo simulations32,43, with preliminary experimental work 
on its imaging potentialities44,45 being also performed. In this paper, we experimentally implement for the first 
time this innovative approach in a clinical scenario by measuring the biological effects as a direct consequence of 
the p-11B reaction.
Besides the advantage of using a neutron-free nuclear fusion reaction, the relevance of this method stems from 
the fact that the p + 11B → 3α cross section becomes significantly high at relatively low incident proton energy, i.e. 
around the Bragg peak region. As schematically depicted in Fig. 1, a proton beam as conventionally used in pro-
tontherapy is drastically slowed down across the tumour (the Bragg peak region). Thus, most of its energy (dose) 
is delivered to the tumour cells. Under the assumption that a given concentration of 11B nuclei is present preferen-
tially, but not exclusively, in the tumour, the arrival of slow protons could trigger a series of fusion events gener-
ating several alpha particles that are localized in the tumour region. In fact, most of the alpha particles generated 
in the proton-boron reaction have an average range in water of less than 30 μm, thus comparable with the typical 
cell size. Hence, even if such particles are mainly produced outside the cell cytoplasm due to sub-optimal boron 
uptake, the probability that they would reach the nucleus and damage the DNA remains very high. Moreover, 
even if a non-negligible concentration of 11B nuclei is present in the healthy tissues surrounding the tumour, the 
number of fusion events (i.e. generated alpha particles), would be relatively low, or completely absent, due the 
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non-favourable incident proton energy spectrum away from the tumour region. This would lead to a more biolog-
ically effective particle dose localization, higher than the one currently achievable with conventional protonther-
apy, thus to a more efficient treatment in terms of an enhancement in cancer cell lethality, especially because of 
the clustered nature of the DNA damage, which is caused by the high-LET alpha particles emitted in the tumour 
region. Hence, protontherapy could acquire the benefits of an enhanced efficiency in cancer cell killing, moving 
close to 12C ion hadrontherapy but without the above-mentioned complications of the latter.
The ballistic advantage granted by the inverted dose-depth profile of charged particles is such that in pro-
tontherapy most of the dose is released mainly in the tumor region (upper panel), cancer cells being represented 
here by purple circles and damaging events by black dots (A): proton-induced damage is similar to that imparted 
to DNA by photons, consisting mainly of isolated lesions (middle and lower panels). If cancer cells are loaded 
with 11B-delivering agents (middle panel, B), as is the case with 10B-enriched compounds in BNCT, unrepairable 
Figure 1. Schematic representation of “conventional” radiotherapy by low-LET proton beams (A) and the 
rationale of boron-enhanced protontherapy (B). Whereas in A) the incident proton beam mainly results in 
isolated, mostly repairable DNA breaks, the extremely localized emission of high-LET radiation produced by 
the proton-boron fusion in the Bragg peak region causes irreparable clustered DNA damage, similar in nature to 
that induced by 12C ions, hence the expected increase in effectiveness at tumor cell killing.
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DNA clustered lesions will be also produced by the high-LET alpha particles generated by the p-11B nuclear fusion 
reaction (lower panel). This in turn leads to a Dose Modifying Factor (DMF) for cancer cell killing while main-
taining beneficial sparing of surrounding healthy tissues (middle panel). Furthermore, for a given clinical case, 
such higher DMF can potentially allow to reduce the overall dose delivered to the patient (lower total number of 
protons used in the number of fractions) compared to a standard treatment without the presence of 11B-delivering 
agents in the tumor.
BSH enhances cancer cell death following proton-irradiation. To test whether the p + 11B → 3α 
reaction results in an enhancement of cell killing by therapeutic proton beam irradiation, cells from the human 
prostate cancer line DU145 were irradiated with graded doses at the middle position of the 62-MeV clinical 
Spread-Out Bragg Peak (SOBP) using the proton beam at the superconducting cyclotron of the INFN-LNS facil-
ity (Catania, Italy). Irradiations were performed in the presence of two concentrations of BSH (see Methods for 
details on the irradiation set-up and BSH pre-treatment). As a control, prostate cancer DU145 cells grown and 
irradiated without BSH were used. The considered BSH concentrations were equivalent to 40 ppm (parts per 
million) and 80 ppm of 11B. These were chosen based on values from the literature on the 10B-enriched BSH 
analogue used in BNCT in order to achieve the optimal intracellular 10B concentration35,46,47. In particular, sim-
ilar boron-equivalent concentration ranges of another BNCT compound, BPA, had been previously used with 
the same cell line in vitro48. Boron treatment enhanced proton biological effectiveness resulting in a significant 
increase in the induction of cell death in DU145 cells as measured by loss of colony-forming ability. Cells that 
were irradiated after pre-treatment with, and in the presence of, boron-containing BSH exhibited a greater radi-
osensitivity in comparison with cells exposed to radiation alone: BSH-treated cells yielded a much steeper clo-
nogenic dose-response curve than that obtained for cells grown and irradiated in BSH-free medium (Fig. 2). 
The clonogenic survival fraction SF following irradiation with protons alone was best fitted to a linear-quadratic 
function of dose, i.e. SF = exp (-α*D-β*D2), with data from proton irradiation in the presence of BSH exhibiting 
a purely exponential behaviour as a function of dose. Least-square fitting parameters are reported in Table 1.
A slight yet not statistically significant effect due to boron concentration was observed. Based upon the meas-
ured survival dose-responses, a calculated DMF of 1.46 ± 0.12 was determined at the 10% survival level (DMF10). 
This indicated that the presence of the boron compound conferred a radiobiological advantage at reducing cell 
Figure 2. Boron-mediated increase in proton irradiation-induced cell death. Clonogenic dose response curves 
of prostate cancer cells DU145 irradiated with therapeutic protons in the presence or absence of BSH at mid-
SOBP. Data are weighted mean values plus standard error from four independent experiments in the case of 
proton irradiation in the absence of BSH (open circles) and in the presence of the compound at the highest 
concentration used (80 ppm, open triangles). Two experiments were performed with cells irradiated in the 
presence of 40 ppm of 11B. X ray-irradiation survival data are also shown for comparison.
α (Gy−1) β (Gy−2)
X ray irradiation 0.222 ± 0.062 0.064 ± 0.014
Proton irradiation in the absence of BSH 0.314 ± 0.022 0.035 ± 0.007
Proton irradiation with 40 ppm 11B 0.614 ± 0.069 —
Proton irradiation with 80 ppm 11B 0.705 ± 0.033 —
Table 1. Cell killing dose-response fitting parameters. Calculated values for the α and β parameters as obtained 
from the fitting of experimental data by the linear-quadratic model for radiation-induced cell killing are 
reported. Statistically equivalent to zero β values were found for proton irradiation in the presence of BSH.
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survival compared to proton irradiation alone. At the concentrations used, BSH was not cytotoxic since the pro-
liferative potential of unirradiated cells as given by cellular plating efficiency was not affected by the presence of 
BSH (Table 2). This means that the measured enhancement of proton effectiveness at cell killing was not contrib-
uted to by cytotoxicity caused by the boron-containing compound per se.
Dependence of BSH-mediated cell killing enhancement upon proton energy. Our working 
hypothesis is that the nuclear fusion p + 11B → 3α (p-B) reaction results in a significant increase in proton biolog-
ical effectiveness due to the short-range high-LET alpha particles it produces. Such a reaction critically depends 
on the incident proton energy; hence, its radiobiological effectiveness can be expected to vary along the clinical 
proton SOBP. To verify this hypothesis, the induction of cell killing in the presence of the boron compound at the 
concentration of 80 ppm 11B (Fig. 2), was investigated irradiating the cancer DU145 cell line at the beam entrance 
(P1 position), at the SOBP distal end (P3 position), and at the middle of the SOBP (P2) as above reported (Fig. 3).
The panel in Fig. 4 shows the clonogenic survival dose-response curves derived from the three positions 
along the SOBP, in the absence or presence of BSH. In line with the expected variation in cell radiosensitivity 
along a clinical SOBP14, proton irradiation alone resulted in a progressive increase in cell killing from P1 to P3. 
Interestingly, data clearly show no effect of BSH at the beam entrance. A DMF of about 1.4 was confirmed at 10% 
cell survival at mid-SOBP: here, fitting parameters were α = (0.309 ± 0.022) Gy−1 and β = (0.040 ± 0.006) Gy−2 
for proton irradiation without BSH and α = (0.653 ± 0.018) Gy−1 in the presence of 80 ppm 11B. At the distal 
end of the SOBP, however, BSH appeared to be even more effective with a recorded DMF of 1.75 ± 0.13: at this 
position, cell killing was best described by a pure exponential for both protons alone and protons in the presence 
of BSH, with values for the α parameter of (0.541 ± 0.027) Gy−1 and (0.952 ± 0.053) Gy−1. These experimental 
results, particularly the lack of a measurable effect due to the presence of 11B at beam entrance where the incident 
proton energy is the highest, confirm that the enhancement of biological effectiveness is caused by the occurrence 
of p-B nuclear fusion events, which have a higher probability (i.e. higher cross section) at relatively low energy 
(MeV level) of the incoming protons, i.e. towards the end of their range.
BSH exacerbates proton irradiation-induced chromosome aberrations and enhances 
complex-type exchanges. Ionizing radiation can give rise to a wide spectrum of structural chromo-
some aberrations or CAs49. It is long-known that CAs are closely linked to clonogenic cell death50, hence an 
increase in cell killing due to the alpha particles produced by the p-B reaction ought to reflect in an increase 
in the yield of CAs. Furthermore, complex-type exchanges, defined as those rearrangements involving at least 
Plating efficiency Baseline CA frequency
No BSH 0.58 ± 0.02 0.027 ± 0.003
40 ppm 11B 0.61 ± 0.04 0.027 ± 0.003
80 ppm 11B 0.60 ± 0.04 0.023 ± 0.003
Table 2. Cytogenotoxicity of BSH alone. Plating efficiency (PE) values and total chromosome aberration (CA) 
yields in unirradiated DU145 prostate cancer cells (second column) and normal epithelial MCF-10A cells (third 
column), respectively, as a function of the amount of BSH. By definition, PE measures the survival of cells in the 
absence of radiation. Similarly, the recorded frequency of CAs in cells not exposed to radiation is referred to as 
baseline CA frequency. Data show lack of BSH-induced cyto- and genotoxicity at the used concentration.
Figure 3. Cell irradiation along the proton SOBP. Measured dose and calculated LET profile for cellular 
irradiation at different positions along the clinical proton SOBP at INFN-LNS, Catania, Italy. Shown are the 
three depths along the SOBP at which cells were irradiated and the corresponding calculated LET values (open 
squares). Dose profiles as obtained by direct measurement by Markus chamber and by Monte-Carlo simulation.
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two chromosomes and generated by at least three breaks, are an archetypical feature of high-LET exposure37,51. 
Therefore, quantification of the proportion of complex-type chromosome exchanges was instrumental to unveil 
the action of high-LET alpha particles generated by the BSH-assisted p + 11B → 3α nuclear reaction. To this 
end, in addition to conventional FISH labelling (which is limited to painting two pairs of homolog chromo-
somes) a more comprehensive investigation was also carried out employing the multicolour(m)-FISH technique, 
which represents the method of choice when an accurate scoring of CAs, particularly of those of complex type, 
is required since it allows analysis of the whole karyotype. This is exemplified by Fig. 5 showing two cells from a 
sample irradiated with 4Gy of protons in the presence of 80 ppm 11B. One cell is conventionally FISH-painted, 
presenting with chromosome rearrangements of complex nature as several portions of the painted chromosomes 
are aberrantly joined with aspecifically stained chromosomes (appearing blue) and with themselves. The other 
cell has been subjected to mFISH analysis revealing a number of aberrations that would have gone undetected 
confining analyses to conventional FISH scoring.
Cancer cells are known to be genetically unstable; hence, they do not lend themselves to reliable assessment of 
radiation-induced DNA damage. Radiation-induced chromosome rearrangements would superimpose onto an 
elevated confounding frequency of baseline damage. Therefore, the non-tumorigenic breast epithelial MCF-10A 
cell line was chosen for scoring of radiation-induced CAs.
In cells not exposed to radiation, BSH per se did not cause significantly higher genotoxic damage compared 
to BSH-untreated cells, in agreement with the lack of cytotoxicity as measured by clonogenic assay (Table 2). 
Conversely, proton irradiation resulted in a higher yield of all CA types in cells treated with BSH compared 
to cells irradiated with protons in the absence of BSH (Fig. 6). As expected, the overall measured frequency 
of CAs raised for all irradiation conditions when using mFISH because of its greater sensitivity. Moreover, the 
boron-mediated enhancement of chromosomal damage is slightly amplified passing from conventional FISH 
Figure 4. Clonogenic survival along the proton SOBP. Data shown here refer to dose-response curves obtained 
at positions P1, P2 and P3 as indicated in Fig. 3 along the clinical proton SOBP. Enhancement of cell killing due 
to the presence of the boron compound (black circles) is null at beam entrance (highest proton mean energy) 
while reaching its maximum at the distal end of the SOBP (lowest mean proton energies).
Figure 5. Analysis of proton irradiation-induced structural chromosome damage. Representative pictures of 
chromosome spreads from 4 Gy-proton irradiated cells treated with 80 ppm of 11B scored by conventional (left) 
and mFISH analysis (right), respectively. Both exhibit complex-type CAs. However, conventional FISH would, 
have detected neither the complex exchanges shown on the right that involves chromosomes 1, 10 e 19, nor the 
two translocations between chromosome 1 and 4 and between 14 e 20, as it paints just chromosomes 1 and 2. 
Using mFISH karyotyping analysis allows therefore more accurate measurement of DNA damage, especially of 
complex type.
www.nature.com/scientificreports/
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scoring to mFISH analysis: the yield of CAs following 2Gy of protons in combination with BSH increased from 
about 0.22 to 0.47 aberrations per cell compared to about 0.11 and 0.20. Furthermore, when mFISH analysis was 
performed, measured CA frequency values “fan out” as dose increases showing a small effect due to 11B concen-
tration at the highest proton dose, i.e. 4Gy, with 80 ppm of 11B appearing slightly more effective than 40 ppm. The 
yield of CAs following x-rays was identical to that measured after exposure to protons in the absence of BSH, in 
line with the observed lack of a significant difference in cell killing between x-rays and protons alone also seen in 
DU145 cancer cells (Fig. 2).
Aberration data were fitted to a linear –quadratic function of the type Y = Y0+α*D+β*D2 where the coeffi-
cient Y0 corresponded to the baseline CA frequency as reported in Table 2. As from mFISH analysis, following 
irradiation in the absence of BSH, no statistically significant value for the parameter α was found, while a value 
of β = (0.051 ± 0.026) Gy−2 could be derived; whereas α and β were (0.154 ± 0.066) Gy−1 and (0.034 ± 0.020) 
Gy−2 for proton irradiation in the presence of 80 ppm of 11B. Because of the purely quadratic nature of the 
dose-response curve for proton irradiation in the absence of BSH, no estimate for DMFmax could be derived as 
this is defined as the ratio of the linear components of the linear-quadratic dose-response curve by analogy with 
the concept of RBE52. DMF values were calculated for two levels of damage instead, that is 20 and 40 aberrations 
per 100 cells. In the case of 20 aberrations per 100 cells, the calculated DMF was about 2.1, whereas a DMF value 
of 1.6 was obtained for the level of 40 aberrations per 100 cells.
The most interesting result, however, came from the analysis of complex-type aberration exchanges. A mark-
edly pronounced occurrence of complex-type exchanges was found in samples treated with BSH compared to 
cells that had been irradiated with protons in the absence of BSH (Fig. 7). After 0.5 Gy of protons, the frequency 
Figure 6. BSH-induced increased induction of chromosome aberrations following proton irradiation. The 
dose-dependent frequency of all chromosome exchanges scored by either conventional FISH painting (left) or 
m-FISH karyotyping (right) is shown for proton irradiation alone (black circles) and for proton irradiation in 
the presence of 11B at concentrations of 40 ppm (open circles) and 80 ppm (down triangles). X-ray data are also 
shown for comparison. In the interest of clarity, fitted curves are shown only for the highest boron concentration 
used (80 ppm, dashed line) and for irradiation with no boron compound (solid line). Data points correspond to 
the mean value measured in at least two independent experiments with standard errors of counts.
Figure 7. Induction of complex-type CAs. A greater proportion of complex chromosome rearrangements was 
found in cells irradiated with protons and treated with BSH than in cells subject to proton irradiation alone. 
Results of scoring with both conventional FISH techniques (left) are shown to highlight how mFISH (right) 
is much more efficient at detecting such type of CAs, which are the most significant biomarker of high-LET 
radiation exposure.
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of complex CAs ranged between 0.025 and 0.028 for BSH-treated cells as opposed to less than 0.004 in the case of 
cells irradiated in the absence of BSH. These values dramatically increased with dose and remained consistently 
higher in the case of BSH-treated cells, reaching about 0.18 and 0.08 after 4 Gy of protons in the presence or the 
absence of BSH, respectively. Occurrence of complex-type exchanges following x-rays is also shown for compar-
ison (Fig. 4) and does not differ from that measured for proton irradiation alone. Analysis by m-FISH confirmed 
such findings revealing how at high dose (4 Gy) conventional FISH scoring tends to underestimate the occurrence 
of complex exchanges, at which dose, as was the case for the total yield of aberrations, m-FISH unveils a slight 
BSH-concentration effect masked by conventional FISH painting.
Taken together, these results strongly support the notion that the presence of BSH results in a significant 
dose-modifying effect on proton irradiation, increasing cell lethality and DNA damage. In particular, the pro-
foundly enhanced yield of complex-type CAs found following proton irradiation of BSH-treated cells points to 
damage brought about by high-LET radiation, thus consistent with the action of the alpha particles produced by 
the p-B fusion reaction.
Discussion
The first experimental evidence of a significant enhancement of proton effectiveness at causing cytogenetic dam-
age cells, through irradiation with a clinical proton beam in the presence of a compound with natural boron 
isotopic content (80% of 11B + 20% of 10B), is reported. The advantage of such a new methodology consists in the 
use of the p-B nuclear fusion reaction, which presents a high cross section for protons with energies in the range 
0.1–10 MeV, i.e. around the Bragg peak. Such a reaction produces three alpha particles with a range comparable 
Table 3. 24Xcyte labelling scheme whereby each chromosome is labelled by the combination of the main five 
fluorochromes.
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to the typical cells’ dimensions. BSH, one of the most commonly used boron-delivering agents in BNCT, served 
as natural boron carrier in our study. The rationale underlying BNCT consists in cancer irradiation by thermal 
neutrons, which results in a highly localized and mostly lethal targeting of cancer cells because of the very short 
range and, hence, of the high LET of the low-energy alpha particles generated in the reaction with the 10B atoms. 
However, despite numerous, carefully designed and generally promising clinical trials53,54, BNCT struggles to 
establish itself in clinical routine, both because of the intrinsically challenging quest for ideal carriers to deliver 
radiobiologically effective concentrations of boron to cancer cells, and because of the limited availability of ther-
mal neutron sources35,47. On the other hand, albeit already being a clinical reality, external beam 12C-ion had-
rontherapy, which is capable of delivering very biologically effective radiation doses with extremely high precision 
to the tumor target, is hampered by economic and radiobiological issues as discussed in the Introduction section.
Currently, the most widespread form of cancer treatment through accelerated charged particles is represented 
by protontherapy, which guarantees the same ballistic precision as 12C ion beams without the added complica-
tions. The disadvantage of protontherapy is, however, a low biological effectiveness at killing cells since protons 
are only about as effective as photons and electrons. The approach we have successfully tested in several exper-
imental runs could represent an enormous step towards the ability to increase the biological efficacy of pro-
ton radiotherapy and therefore expand its use towards the treatment of radioresistant tumours by coupling the 
already favorable spatial characteristics of protons with the capacity to trigger the proposed reaction exclusively 
inside the tumor. In principle, this would enable the avoidance of the intrinsic uncertainties and enormous han-
dling complications associated with the use of neutron beams in BNCT and could lead to an increase of proton 
biological effectiveness towards values closer to those exhibited by 12C-ions.
The biological effects of the p-B fusion reaction were investigated by measuring clonogenic cell death and 
chromosome aberrations (CAs) in a prostate cancer cell line (DU145) and in a non-tumorigenic epithelial breast 
cell line (MCF-10A), respectively. The latter was best suited to investigate chromosomal damage as opposed to 
genomically unstable cancer cells.
We found that proton irradiation-induced cellular lethality was greatly enhanced by irradiating cells that 
had been pre-treated with BSH. In particular, our results for survival of DU145 cells following low-LET proton 
irradiation alone are in line with those obtained at another protontherapy facility by Polf et al.55, who studied the 
radiosensitizing effects of Au nanoparticles. They actually reported an enhancement of proton biological effec-
tiveness of smaller magnitude compared to that experimentally achieved by us. Moreover, cellular survival values 
measured in our experiments using BSH are essentially identical to those reported by Yasui et al.48, where DU145 
cells were exposed to neutrons in presence of BPA the other commonly used boron-delivering agent).
To further consolidate our experimental findings as due to the occurrence of several p-B fusion reaction 
events, cell survival dose response curves were obtained irradiating DU145 cells at three different positions along 
the proton SOBP. The results strongly argue in favour of an incident beam energy-dependent increase in pro-
ton biological effectiveness since no dose modifying effect could be measured when cells were irradiated in the 
presence of BSH at the beam entrance, whereas an apparent increase in effectiveness was measured as cells were 
irradiated at the distal end of the SOBP, in agreement with the cross section of the p-B fusion reaction, which 
increases with the decrease of mean proton beam energy (see Fig. 8 below).
Investigation of structural DNA damages in the form of CAs not only confirmed that the effectiveness of 
cellular proton irradiation is enhanced by the presence of boron, as more CAs were found in samples irradiated 
in the presence of BSH, but the greater occurrence of complex-type exchanges, a well-acknowledged biomarker 
of high LET radiation exposure, also strongly suggests that such an enhancement could be explained by the 
action of the high-LET alpha particles. To unveil the potentiating genotoxic action of the boron-carrier BSH two 
FISH techniques were used: conventional FISH painting and multicolour (m-)FISH. The former allows scoring 
Figure 8. Experimental cross sections. Proton-11B total reaction cross section for the most probable α1 channel 
decay (from EXFOR database).
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of chromosome aberration (CAs) types by labelling a limited number of chromosome pairs. By multicolour 
(m)-FISH, on the other hand, the whole karyotype can be scored thus allowing to detect aberrations that would 
involve additional chromosomes and would go undetected by the first method. For most purposes, measurement 
of CA by conventional FISH provides a reliable assessment of radiation-induced genotoxicity. However, mFISH 
is typically used when a more accurate estimate of complex-type exchanges is needed. Firstly, a greater aberration 
frequency was found among BSH-treated cells. Following the highest dose of protons used (4 Gy) in the presence 
of 40 ppm of 11B, the observed frequencies of dicentrics (0.144 ± 0.004) and rings (0.064 ± 0.008) are consistent 
with those of 0.171 ± 0.0175 and 0.029 ± 0.007, respectively, found by Schmid et al.56 in human lymphocytes at 
the highest dose of thermal neutrons used by them (i.e. 0.248 Gy) and at a similar 11B-equivalent concentration 
(30 ppm). In addition, a significantly higher proportion of complex chromosome rearrangements in BSH-treated 
cells compared to controls following proton irradiation was found. This arguably points to an LET-dependent 
effect since complex CAs are a well-known cytogenetic signature of exposure to high-LET radiation. In fact, it 
is also known that a greater biological effectiveness of densely ionizing radiation is a direct consequence of the 
physical pattern of energy deposition events along and around its tracks. Low-LET ionizing radiation such as 
x- or γ-rays mainly damage cells through short-lived bursts of free radicals (e.g. reactive oxygen species), gener-
ated by its interaction with the intracellular environment. This causes isolated lesions at the DNA level, the most 
detrimental of which for cell survival are double-strand breaks (DSBs). However, the much denser thread of 
ionization events specific to track-structured high-LET particle radiations, results in many closely spaced clusters 
of multiply DNA damaged sites, comprising DSBs together with single-strand breaks and damaged bases, which 
cause the cellular repair system to be error-prone. Hence, such lesions either are left unrepaired, which explains 
the greater efficiency of high-LET radiations at cell killing, or undergo misrepair. In the latter case, since single 
densely ionization tracks can simultaneously cause breaks in far apart stretches of DNA, i.e. belonging to separate 
chromosome domains, defective repair will lead to a higher frequency of DNA mis-rejoining events occurring 
between several chromosomes compared to the case following low-LET radiation, also known as complex-type 
exchanges. In BSH-treated irradiated cells, the proportion of such complex-types of aberrations relative to total 
exchanges ranged between 30% and 42% while in the case of proton irradiation without boron was between 6% 
and 15%. Moreover, the estimated ratio of complex- to simple-exchanges ranged between 0.59 and 0.71, i.e. simi-
lar to value reported in the literature, e.g. 0.64 for 0.5 Gy when only alpha particles were delivered to the biological 
sample consisting of first-division human lymphocytes scored with conventional FISH painting, i.e. one of the 
cytogenetic techniques used in our work57. Analysis by m-FISH painting corroborated the results obtained by 
conventional FISH analysis providing an exhaustive and incontrovertible evidence in support of a BSH-assisted 
increase of proton irradiation –induced complex aberrations.
Although measurements of 11B incorporation by cells were not performed, both drug pre-treatment times and 
concentrations were chosen according to available literature data for the use of the boron-carrier BSH in BNCT, 
according to which the optimal conditions to reach an ideal boron concentration in cells is 20 µg per grams of 
tissue or 109 atoms per cell58. Indeed, although 10B-enriched BSH is known for its poor permeabilization through 
cell membranes, its use is facilitated by a higher boron content compared to the other widely used boron-delivering 
compound, such as BPA. However, the alpha particles emitted via the p + 11B → 3α reaction present average energies 
around 4 MeV MeV, which correspond to ranges in tissues of a few tens of microns, thus ensuring a severe cellular 
DNA damage even if BSH is not incorporated inside the cell but sits on its membrane. Moreover, the ballistic prop-
erties of the incident proton beam, whereby proton energies drastically decrease in correspondence with the tumour 
volume, ensure negligible nuclear fusion events even in the worst-case scenario where the delivery agent containing 
11B nuclei is also heavily present in the healthy tissues surrounding the tumour. Furthermore, the presence of 10B in 
the proposed method allows triggering various nuclear reactions that generate prompt γ-rays, thus being potentially 
useful for a simultaneous treatment-and-diagnostics approach32,43,59.
The radiobiological data reported in this work suggest that the p + 11B → 3α reaction as being responsible 
for the observed increase in the biological effectiveness of a clinical proton beam. However desirable, we cannot 
currently provide a simple analytical computation able to explain our results, for instance by correlating the bio-
logical effect with the total number of α-particles that can be expected to be generated under our experimental 
conditions. A possible approach could be trying to calculate the increase in the overall dose and/or LET due to 
such particles. The current knowledge of biological radiation action has nonetheless established that, the biolog-
ical effects of low-energy high-LET radiations cannot be interpreted solely on the basis of macroscopic concepts 
like the absorbed dose or the average LET distributions. This is due to the intrinsically inhomogeneous nature of 
energy deposition events along radiation tracks, which becomes more significant with their increasing ionization 
density. Therefore, micro- and nano-dosimetric approaches must be taken into account to analyse the effects aris-
ing at cellular level. In addition, the role of extra-targeted phenomena, such as the bystander effect whereby cells 
that have not been traversed directly by radiation tracks may express cytogenetic damage, is still largely undeter-
mined in such scenario60, thereby contributing to the overall uncertainty between the physical dose distribution 
at the micro or nano-dosimetric level and at the cellular one..
In conclusion, if further confirmed by both in vitro and pre-clinical investigations, our results represent an 
important breakthrough in cancer radiotherapy, particularly in the treatment of such disease by using accelerated 
proton beams since it may significantly enhance its effectiveness without foreseeable patients’ health complica-
tions and added financial costs.
Methods
Cell cultures. Prostate cancer cell line DU145 and the spontaneously immortalized, no-transformed human 
mammary epithelial MCF-10A cells (kindly donated by prof. K. Prise, School of Medicine, Dentistry and 
Biomedical Sciences, QUB, UK) were grown in 25-cm2 (T25) standard tissue culture flasks, routinely subcultured 
and maintained at 37 °C in a humidified atmosphere (95% air, 5% CO2). DU145 cells were used to assess possible 
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enhancement by boron of proton-induced cancer cell death while chromosomal DNA damage was investigated 
in MCF-10A cells. DU145 cells were grown in RPMI medium supplemented with 10% fetal bovine serum and 1% 
antibiotics. Two media were instead needed for MCF-10A cells, one for optimal growth conditions and the other 
for resuspension and quenching of trypsin, as described in detail by Debnath et al.61. Two days before irradiation 
DU145 and MCF-10A cells were seeded in T25 flasks at 105 and 6 105 cells/flask, respectively.
BSH preparation and treatment. A 1-g vial of sodium mercaptododecaborate or N-BSH, Na2 [B12H11SH], 
FW 219.87, was purchased from KATCHEM Ltd. (Czech Republic). The working concentrations of 80 and 40 ppm 
of 11B corresponded to 0.17 mg/ml and 0.08 mg/ml of BSH, respectively. BSH was decanted at the necessary amounts 
according to the total volume of the medium, in which the compound was thoroughly dissolved by simple agitation 
just prior to cell treatment. Boron cellular conditioning started 7 hrs prior to irradiation: the cell growth medium 
was aspirated and replaced with 5 ml of BSH-containing medium. Ordinary BSH-free growth medium was replaced 
into flasks that were used as controls. Just before irradiation, flasks were completely filled with the respective media 
(with or without BSH) to prevent cells from drying since flasks are irradiated standing vertically in front of the beam.
p + 11B → 3α nuclear fusion. The p + 11B → 3α nuclear fusion reaction at low energy can be basically 
described as a two-step reaction due to its behaviour at the three resonant energies (0.162 MeV, 0.675 MeV and 
2.64 MeV). Firstly, a proton, interacting with 11B, induces the formation of a 12C* compound nucleus formed in 
the 2- or 3- excited state. If the 12C* nucleus is formed in its 2- state, it will decay to the first 2+ stat of 8Be emitting 
one alpha-particle with l = 362. If the 12C* nucleus is formed in its 3- state, then the primary alpha particle can be 
emitted either with l = 1 from the decay to the first 2+ 8Be excited state, or with l = 3 from the decay to the 0 + 8Be 
ground state. In either case, the remaining 8Be (2+ or 0+) nucleus immediately decays into two secondary alpha 
particles with l′ = 2. Alpha particles emitted in the first stage present a well-defined energy distribution and are 
commonly referred to as α0 and α1 if the 8Be 2+ or the 0+ states are populated, respectively. Few authors62,63 
report that a very unlikely fourth channel, characterized by a maximum cross section of 10 μb in the 2.0–2.7 MeV 
energy range, can also be activated. In this case the 12C* directly breaks into three α particles skipping the inter-
mediate 8Be stage, which show a continuous energy distribution.
Figure 8 reports some of the available experimental data62,63 for the total production cross section of the 
p + 11B → 3α reaction as function of the mass centre energy and for the α1 channel. For low energies (0.1–5 MeV) 
the reaction cross sections become significantly high, thus maximising the alpha particle production around the pro-
ton Bragg peak region, an advantageous feature for the alternative protontherapy approach proposed in this work.
Irradiation. Irradiations were performed using the 62-MeV proton beam generated by the superconducting 
cyclotron clinically used at the CATANA (Centro di AdroTerapia ed Applicazioni Nucleari Avanzate)64,65 eye pro-
ton therapy facility of the Italian Institute for Nuclear Physics in Catania, Italy. The CATANA irradiation setup for 
biological samples is described in detail elsewhere65. The clinical Spread Out Bragg Peak (SOBP) range was 30 mm 
in water and cells were positioned at the depth of 24.86 mm water equivalent (calculated incident LET ~ 5 keV/μm), 
to the middle of the SOBP. Absolute absorbed dose is measured in water, by means of a plane-parallel PTW 34045 
advanced-type Markus ionisation chamber, according to the International Atomic Energy Agency Technical Report 
Series 398 Code of practice66. The absorbed dose in water per monitor unit (cGy/M.U.) for the specific modulated 
beam used to irradiate the cells was measured at the isocenter. The dose measurements were carried out at the 
depth corresponding to the middle of the SOBP, using a reference 25 mm diameter circular collimator65. The clinical 
proton beam calibration was performed just before each irradiation; the variation of beam calibration on the vari-
ous experiments resulted to be within 3%. Overall uncertainty in absolute dose measurement is kept within 1.5%. 
Details on the irradiation beamlines, dosimetric procedures and related uncertainties for irradiation conditions can 
be found elsewhere66. For measurement of cell killing, proton doses of 0, 0.5, 1, 2, 3 Gy were used. For 80 ppm of 11B 
the effects of a dose of 4 Gy were also tested. One cell culture flask was used for each dose for all BSH concentrations 
in each experiment. For chromosome aberration studies, three doses were used: 0.5, 2 and 4 Gy. Two flasks per dose 
were used for all BSH concentrations. Four independently repeated experiments were performed for clonogenic 
survival with protons alone and 80 ppm of 11B, and two independent experiments for clonogenic cell death with 40 
ppm 11B. Two independent experiments were carried out for chromosome aberration analysis.
In the case of measurement of clonogenic survival along the proton SOBP, appropriate stacks of PMMA 
degraders were realised to achieve varying depths along the dose-depth profile using the same setup as described 
in Chaudray et al.14. Low-LET reference irradiations were carried out at Physics Department, University of Naples 
Federico II, employing a 250 kVp radiogen x-ray STABILIPAN machine (Siemens), with 1-mm Cu filter and a 
dose rate of about 1.2 Gy min−1.
Measurement of cell death. Radiation-induced cell death was assessed by means of the clonogenic test, 
the gold standard for measuring cellular radiosensitivity. According to this assay, a cell survives irradiation if it 
retains its proliferative potential and it is thus capable of forming a colony composed of at least 50 cells. After irra-
diation, the medium was discarded from the flasks, and DU145 cells were detached, counted by haemocytometer 
and re-plated at opportune densities. They were then allowed to grow for colony formation in BSH-free medium. 
Four replicates for each dose were used for statistical data robustness. Clones were fixed and stained by crystal 
violet after 10 days. Surviving fractions (SF) are obtained by dividing the number of clones by the number of cells 
seeded at a given dose D, normalized by the plating efficiency (PE), that is the “surviving” of cells in the absence 
of radiation according to the expression SFDoseD = [Number of clones/number of cells]DoseD/(PE). Experimental 
data were fitted to the linear-quadratic equation that best describes low-LET radiation induced cell death SF = exp 
(-α*D-β*D2).
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Chromosomes aberration analysis. After irradiation, MCF-10A cells were kept in BSH-free medium 
for up to 36 h. Genotoxic action of radiation was studied by scoring structural aberrations in chemically induced 
interphase chromosomes according to the Premature Chromosome Condensation (PCC) technique. Cells were 
incubated for 30 min with calyculin A (50 ng/mL, Sigma-Aldrich) for PCC induction as elsewhere described67. 
To collect PCC spreads, cells were trypsinized, centrifuged at 300g for 8 min, then the pellet was resuspended 
for 25 min in hypotonic solution (75 mM KCl at 37 °C), and fixed on ice in freshly prepared Carnoy solution 
(3:1 v/v methanol/acetic acid). Spreads were then dropped on pre-warmed (42 °C) wet slides and air-dried at 
room temperature. Conventional Fluorescence In Situ Hybridization (FISH) painting was conducted by using 
whole-chromosome fluorescence-labelled DNA painting probes directed to chromosomes 1 and 2 following the 
manufacturer’s recommendations (MetaSystems, Germany). Denaturation (72 °C for 3 min) followed by hybridi-
zation (37 °C overnight) of slides was performed using a hand-free HYBrite chamber system. Unlabeled chromo-
somes were counterstained with 12 ml 4, 6-diamidino-2-phenylindole (DAPI) staining. For m-FISH, the 24XCyte 
probe by MetaSystems was applied to chromosomes harvested as above described. The labelling kit contains five 
fluorochromes:
•	 CyTM5 - Cyanine 5, fluorescing in the red region (649 nm excitation, 670 nm emission);
•	 DEAC (DiEthylAmino-Coumarin) - λex = 409 nm, λem = 473 nm;
•	 FITC (Fluorescein IsoThioCyanate) - λex = 495 nm, λem = 525 nm;
•	 Spectrum OrangeTM - λex = 554 nm, λem = 587 nm;
•	 Texas Red® - λex ~ 596 nm, λem ~ 620 nm.
Software ISIS® imaging system (MetaSystems) attributes a false color pattern depending on overlap signals 
intensity, according to 24XCyte labeling scheme shown below (Table 3).
As per manufacturer’s directions, chromosomes and probe were denaturated by sequential treatment by 2X 
Saline-Sodium Citrate (SSC) solution at 70 °C for 30 min, followed by room temperature (RT) bathing in 0.1x 
SSC for 1 min, by RT rinse in 0.07 NaOH for 1 min, 4 °C wash in 0.1X and 2X SSC for 1 min each. Final step was 
sequential washing in ethanol series (70%, 95% and 100%). While slides air-dried, probe was denaturated by 
incubating at 75 °C incubation in a water bath for 5 min, ice-cold cooling for 30 min and incubation at 37 °C for 
30 min. Denatured probe was then applied to the slide (12 μl for a 24 × 24 mm2 coverslip). Hybridization was thus 
carried out for 48 h using the above-mentioned HYBrite chamber. After post-hybridization washing (0.4X SSC, 
pH 7.0–7.5, at 72 °C; RT 2X SSC, pH 7.0–7.5, containing 0.05% Tween20®), DAPI/antifade (250 ng/ml) counter-
staining was applied.
For conventional FISH scoring, slides were viewed with an epi-fluorescence microscope connected to a 
computer-controlled system (Metafer 4 software, MetaSystems), for automated slide scanning and three-color 
image acquisition. Chromosome analysis was carried out on stored images. Scoring was conducted blind by the 
same scorer. Not less than 500 chromosome spreads for each dose were scored (at least 1,500 for nonirradiated 
controls). Karyotype reconstruction and analysis was manually carried out using an Axio Imager M1 fluorescence 
microscope (Zeiss) with the help of the ISIS software for image processing. At least 200 chromosome spreads 
were analyzed for each experimental point. All types of aberrations were scored separately and categorized as 
simple exchanges (i.e. translocations and dicentrics), either complete or incomplete, acentric fragments and com-
plex exchanges 68. For this study’s purpose, however, data herein presented are relative to the total chromosomal 
exchange frequency and to the complex-type exchange frequency. Frequency of total aberration exchanges was 
fitted to the equation Y = Y0+α*D+βD2.
Statistical analysis. For analysis of the dose – response relationships for cell killing and chromosome aber-
ration frequency, curve fitting was performed by nonlinear least square minimization (Marquardt’s algorithm) 
using SigmaPlot 12.5 software (SPSS, USA). Poisson statistics was assumed to derive standard errors on aber-
ration frequencies. Experimental surviving fraction data in clonogenic assays are affected by several sources of 
errors, such as those associated with cell counts and cell dilutions, which are not taken into account by simple 
calculations of the standard error affecting colony counting. A more precise approach is needed to determine the 
experimental error on the plating efficiency PE as above defined and here recalled for convenience:
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Recalling the definition of Surviving Fraction at a given dose D:
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In the interest of simplicity, it can be assumed that the mean number of cells seeded that appears in the above 
formula is devoid of error, which is reasonable since cell counting error is taken care of in the SE (PE). This means 
treating Xcells as a constant; hence we can define 
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 as SF, with its error being (SEcolonies)/ X( )cells .Hence, SE(SFD) 
can be determined as follows:
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In these calculations, we assumed that observed CV is always greater than Poisson CV on all counts, of either 
colonies or cells; wherever this was no the case, we corrected the experimental SE by multiplying the mean (of cell 
or colony counts) by the Poisson CV.Error on calculated DMF at 10% survival (SF) level defined as:
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Dose uncertainties were derived using error propagation from the linear-quadratic equation SF = exp 
(−α*D-β*D2), which in its most general formulation reads as:
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Rigorously, in formula 7 there is also the covariance of the parameters α and β, which, for clonogenic survival 
curves, is negative as they are weakly anti-correlated, hence, this term is neglected to avoid underestimation of the 
error, with the partial derivatives of the dose with respect to α and β being
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